Calcineurin Inhibitor Market, By Drug Type, By Route of Administration, By Indication (Organ Transplant Rejection Prevention, Autoimmune Diseases, Ophthalmic Diseases, By Distribution Channel, By End User, By Geography

Description

Global calcineurin inhibitor market size is expected to be valued at US$ 10.07 Bn in 2023, and is expected to reach US$ 20.64 Bn by 2030, exhibiting a CAGR of 10.8% during the forecast period of 2023 to 2030.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 10.07 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	10.80%	2030 Value Projection:	US$ 20.64 Bn

Figure 1. Global Calcineurin Inhibitor Market Share (%), By Region, 2023

Calcineurin inhibitors are a type of immunosuppressant. These drugs work by suppressing the activity of the immune system to prevent it from attacking the transplanted organ. They are commonly used in organ transplantation, especially kidney, heart, and liver transplants. There are two main types of calcineurin inhibitors: cyclosporine and tacrolimus. Both of these drugs have been proven to be effective in preventing organ rejection, but they can also have serious side effects, including kidney damage, high blood pressure, and an increased risk of infections and cancer. The global calcineurin inhibitors market is expected to grow due to the increasing prevalence of organ transplantation and autoimmune diseases. The market is also driven by the development of new drugs and the expansion of indications for existing drugs. However, the market growth may be hindered by the side effects of these drugs and the high cost of transplantation. Key players in the global calcineurin inhibitors market include Novartis AG, Astellas Pharma Inc., Allergan, Inc., and Pfizer Inc. These companies are focusing on research and development activities to develop new and improved calcineurin inhibitors. In terms of geography, North America holds the largest share of the calcineurin inhibitors market, followed by Europe. This is due to the high prevalence of organ transplantation and autoimmune diseases in these regions. The market in Asia Pacific is expected to grow at a significant rate due to the increasing healthcare expenditure and the growing awareness about organ transplantation in this region.

Market Dynamics:

Increasing cases of autoimmune diseases and organ transplantation is expected to drive growth of the global calcineurin inhibitor market in the near future. Increasing demand for the calcineurin inhibitors to prevent rejection of transplanted organs is the major driving factor. For instance, in December 2020, Biocon, an innovation-led global biopharmaceutical company, announced the launch of Tacrolimus capsules in the U.S. Tacrolimus is a calcineurin inhibitor, an immunosuppressant used in the treatment of organ transplant patients that reduces the body's ability to reject a transplanted organ.

However, side effects associated with calcineurin inhibitors such as skin irritation and gastrointestinal disturbances may hamper the market growth. Moreover, risks connected with overdosing of the orally administered drugs such as nephrotoxicity and hepatotoxicity are also expected to hamper the market growth in the near future.

Key features of the study:

This report provides in-depth analysis of the global calcineurin inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global calcineurin inhibitor market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy's Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global calcineurin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcineurin inhibitor market

Detailed Segmentation:

Global Calcineurin Inhibitor Market, By Drug Type:
- Cyclosporine
- Tacrolimus
- Pimecrolimus
- Voclosporin
- Others
Global Calcineurin Inhibitor Market, By Route of Administration:
- Oral
- Topical
- Intravenous
Global Calcineurin Inhibitor Market, By Indication:
- Organ Transplant Rejection Prevention
- Autoimmune Diseases
- Ophthalmic Diseases
- Other Dermatological Conditions
Global Calcineurin Inhibitor Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Calcineurin Inhibitor Market, By End User:
- Hospitals
- Specialty Clinics
- Dermatology Centers
- Transplant Centers
Global Calcineurin Inhibitor Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Novartis AG
- Amgen
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Incyte Corporation
- Chiesi Farmaceutici S.p.A.
- Astellas Pharma Inc.
- Sanofi SA
- Bristol Myers Squibb Company
- Mylan N.V.
- Dr. Reddy's Laboratories Ltd.
- Senju Pharmaceutical Co. Ltd
- Abbott
- Lupin Limited
- Vibcare Pharma Pvt. Ltd.

Product Code: CMI5848

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Calcineurin Inhibitor, By Drug Type
- Market Calcineurin Inhibitor, By Route of Administration
- Market Calcineurin Inhibitor, By Indication
- Market Calcineurin Inhibitor, By Distribution Channel
- Market Calcineurin Inhibitor, By End User
- Market Calcineurin Inhibitor, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Calcineurin Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Calcineurin Inhibitor Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2023 - 2030
- Segment Trends
Cyclosporine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Tacrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Pimecrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Voclosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Calcineurin Inhibitor Market, By Route of Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019- 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Calcineurin Inhibitor Market, By Indication, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019- 2030
- Segment Trends
Organ Transplant Rejection Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Ophthalmic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Other Dermatological Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Calcineurin Inhibitor Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019- 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

9. Global Calcineurin Inhibitor Market, By End User, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019- 2030
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Dermatology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Transplant Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

10. Global Calcineurin Inhibitor Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019 - 2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
South Africa
North Africa
Central Africa

11. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
F.Hoffmann-La Roche Ltd
Pfizer Inc.
Incyte Corporation
Chiesi Farmaceutici S.p.A.
Astellas Pharma Inc.
Sanofi SA
Bristol Myers Squibb Company
Mylan N.V.
Reddy's Laboratories Ltd.
Senju Pharmaceutical Co. Ltd
Abbott
Lupin Limited
Vibcare Pharma Pvt. Ltd.
Analyst Views

12. Section

Research Methodology
About us